Allogene building Cali allogeneic CAR-T facility

Dan Stanton, Managing editor

February 22, 2019

1 Min Read
Allogene building Cali allogeneic CAR-T facility
Image: iStock/the_guitar_mann

Allogene has confirmed it is building a 118,000 square foot cell therapy manufacturing facility in Newark, California to support its AlloCAR T candidates.

Last month, Allogene Therapeutics revealed to BioProcess Insider its intentions to establish a manufacturing facility in the San Francisco Bay area.

The firm did not provide projections at the time, but has now said it has entered a lease agreement at a site in Newark, California to build a 118,000 square foot cell therapy manufacturing facility.


Image: iStock/the_guitar_mann

“This manufacturing facility and continued build out of our in-house process development and characterization capability will allow us to advance manufacturing and secure the supply of our AlloCAR T therapies,” Alison Moore, CTO of Allogene said in a statement.

Allogene, founded last year by former Kite Pharma executives, aims to bring allogeneic chimeric antigen receptor (CAR) T-cell therapies to the market.

According to the firm, its AlloCAR T therapies are made using T cells harvested from healthy donors that are then engineered to express CARs designed to recognize certain cell surface proteins expressed on hematologic or solid tumors. Genes within T cells are then edited to reduce the risk of graft versus host disease and allogeneic rejection.

Lead candidate UCART19 is being co-sponsored by Servier and is one of a number of partnered CAR-T programs Allogene taken over from Pfizer in April 2018. Pfizer traded its rights to UCART19 and 16 preclinical CAR-T candidates for a 25 percent stake in Allogene.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like